Semaglutide is a glucagon-like peptide-1 receptor agonist approved for weight management and diabetes treatment, but only when administered correctly beneath the skin
, -1 ,
Regular physical activity and keeping track of calories can make a big difference in achieving weight goals
While more research is needed, these findings support the idea that GLP-1s may dampen the brains reward response to alcohol in much the same way they appear to reduce cravings for food
If you experience mood changes, the team can investigate nutritional gaps, adjust your semaglutide schedule, or recommend the Precision Peptide Genetic Test to understand your individual risk profile
When combined with increased physical activity and a low-calorie diet, semaglutide (Wegovy) is indicated for weight management in patients with: Obesity (BMI of 30 kg/m or higher) Overweight (BMI of 27 kg/m or higher) with at least one weight-related health condition such as high cholesterol levels, hypertension (high blood pressure), heart disease, and type 2 diabetes Mechanism of action Semaglutide is a GLP-1 agonist that slows digestion, reduces appetite, and stabilizes blood sugar by working in the following ways: It mimics the action of glucagon-like peptide-1 in the lateral hypothalamus (hunger control centre), which suppresses appetite and gives you a feeling of satiety
